Functional transcriptomic annotation and protein–protein interaction network analysis identify NEK2, BIRC5, and TOP2A as potential targets in obese patients with luminal A breast cancer
Open Access
- 12 January 2018
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 168 (3) , 613-623
Abstract
Purpose Although obesity is a risk factor for breast cancer, little effort has been made in the identification of druggable molecular alterations in obese–breast cancer patients. Tumors are controlled by their surrounding microenvironment, in which the adipose tissue is a main component. In this work, we intended to describe molecular alterations at a transcriptomic and protein–protein interaction (PPI) level between obese and non-obese patients. Methods and results Gene expression data of 269 primary breast tumors were compared between normal-weight (BMI < 25, n = 130) and obese (IMC > 30, n = 139) patients. No significant differences were found for the global breast cancer population. However, within the luminal A subtype, upregulation of 81 genes was observed in the obese group (FC ≥ 1.4). Next, we explored the association of these genes with patient outcome, observing that 39 were linked with detrimental outcome. Their PPI map formed highly compact cluster and functional annotation analyses showed that cell cycle, cell proliferation, cell differentiation, and cellular response to extracellular stimuli were the more altered functions. Combined analyses of genes within the described functions are correlated with poor outcome. PPI network analyses for each function were to search for druggable opportunities. We identified 16 potentially druggable candidates. Among them, NEK2, BIRC5, and TOP2A were also found to be amplified in breast cancer, suggesting that they could act as strategic players in the obese-deregulated transcriptome. Conclusion In summary, our in silico analysis describes molecular alterations of luminal A tumors and proposes a druggable PPI network in obese patients with potential for translation to the clinical practice.Keywords
Funding Information
- Instituto de Salud Carlos III (PI16/01121)
- Excma. Diputación Albacete (DIPUAB17GALANMOYA)
- Universidad de Castilla-La Mancha (POSTUCLM15-7)
This publication has 43 references indexed in Scilit:
- Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cellsOncogene, 2013
- Kinesins and cancerNature Reviews Cancer, 2012
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progressionCancer and Metastasis Reviews, 2011
- Using graph theory to analyze biological networksBioData Mining, 2011
- The landscape of somatic copy-number alteration across human cancersNature, 2010
- Antimitotic effect of the retinoid 4-oxo-fenretinide through inhibition of tubulin polymerization: a novel mechanism of retinoid growth–inhibitory activityMolecular Cancer Therapeutics, 2009
- Outcome of Patients With Early-Stage Breast Cancer Treated With Doxorubicin-Based Adjuvant Chemotherapy As a Function of HER2 and TOP2A StatusJournal of Clinical Oncology, 2009
- Nek2 as a novel molecular target for the treatment of breast carcinomaCancer Science, 2009
- The Centrosomal Kinase Nek2 Displays Elevated Levels of Protein Expression in Human Breast CancerCancer Research, 2004